Over the past decades, a multitude of experimental drugs have been shown to delay
disease progression in preclinical animal models of amyotrophic lateral sclerosis (ALS) but …

The blood–spinal cord barrier (BSCB), a physical barrier between the blood and spinal cord
parenchyma, prevents the toxins, blood cells, and pathogens from entering the spinal cord …

Despite wide genetic, environmental and clinical heterogeneity in amyotrophic lateral
sclerosis, a rapidly fatal neurodegenerative disease targeting motoneurons …

Acute spinal cord injury (SCI) induces severe neuroinflammation, which increases
intermediary filaments and neurodegeneration. Previous studies have shown that a basic …

Neuroinflammation is critically involved in the repair of spinal cord injury (SCI), and
macrophages associated with inflammation propel the degeneration or recovery in the …

There are various clinical treatments for traumatic brain injury, including surgery, drug
therapy, and rehabilitation therapy; however, the therapeutic effects are limited. Scaffolds …

Spinal cord injury (SCI) can cause locomotor dysfunctions and sensory deficits. Evidence
shows that functional nanodrugs can regulate macrophage polarization and promote anti …

Endothelial progenitor cells (EPCs), which are a type of stem cell, have been found to have
strong angiogenic and tissue repair capabilities. Extracellular vesicles (EVs) contain many …

Background Spinal cord injury (SCI) causes devastating neurological damage, including
secondary injuries dominated by neuroinflammation. The role of Apelin, an endogenous …

RIP1 kinase is proposed to play a critical role in driving necroptosis and inflammation in
neurodegenerative disorders, including Amyotrophic Lateral Sclerosis (ALS). Preclinical …